Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 7:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 926 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: PSORIASIS Clear all

Conditions: Psoriatic Arthritis
Interventions: Zasocitinib, Active Comparator, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 1,583 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 50
States / cities: Chandler, Arizona • Phoenix, Arizona • Fountain Valley, California + 44 more

Conditions: Psoriasis, Obesity
Interventions: Weight Loss; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Psoriasis
Interventions: CNTO 1959; Placebo; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 8
States / cities: Los Angeles, California • San Diego, California • Miramar, Florida + 5 more

Conditions: Psoriatic Arthritis
Interventions: Ixekizumab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 394 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 22
States / cities: Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 19 more

Conditions: Psoriasis
Interventions: Ruxolitinib phosphate cream, Dovonex® calcipotriene 0.005%, Diprolene® AF betamethasone dipropionate 0.05% cream., Placebo cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 6
States / cities: Vallejo, California • Boston, Massachusetts • Rochester, New York + 3 more

Conditions: Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
Interventions: Bimekizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 1,353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 48
States / cities: Glendale, Arizona • Phoenix, Arizona • Bakersfield, California + 43 more

Conditions: Psoriasis, Immunomodulation
Interventions: tofacitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Plaque Psoriasis
Interventions: NIS; Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 899 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 37
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Rogers, Arkansas + 34 more

Conditions: Psoriatic Arthritis
Interventions: CNTO 1275 63 mg, Placebo; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 12
States / cities: Macon, Georgia • Boise, Idaho • Normal, Illinois + 9 more

Conditions: Plaque Psoriasis
Interventions: Apremilast; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Plaque Psoriasis
Interventions: JNJ-77242113, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 12 Years and older
Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 28
States / cities: Scottsdale, Arizona • Fort Smith, Arkansas • Encinitas, California + 24 more

Conditions: Rheumatoid Arthritis, Psoriatic Arthritis, Polyarthritis
Interventions: 11th grade reading level arthritis materials, Interactive in-person arthritis education; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Psoriasis
Interventions: M518101, Vehicle; Drug
Lead sponsor: Maruho North America Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Tustin, California

Conditions: Psoriasis Vulgaris
Interventions: CTLA4Ig / Abatacept; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 1998
U.S. locations: 10
States / cities: San Diego, California • Chicago, Illinois • Boston, Massachusetts + 7 more

Conditions: Moderate-to-severe Chronic Plaque Psoriasis
Interventions: Tildrakizumab, Placebo, Etanercept; Drug
Lead sponsor: Sun Pharmaceutical Industries Limited; Industry
Eligibility: 6 Years to 215 Months
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 5
States / cities: Fountain Valley, California • Thousand Oaks, California • Miami, Florida + 1 more

Conditions: Ankylosing Spondylitis, Autoimmune Disease, Crohn Disease, Enteropathic Arthritis, Enteropathic Spondylitis, Inflammatory Bowel Disease, Melanoma, Psoriasis, Psoriatic Arthritis, Reactive Arthritis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Ulcerative Colitis
Interventions: Best Practice, Educational Intervention, Interview, Questionnaire Administration, Survey Administration; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Psoriasis
Interventions: UV-B Lightsource and Fiber Optic Comb; Device
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Psoriasis, Pain
Interventions: Heating Pack, Ice pack; Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: Not listed
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Psoriasis
Interventions: BI 655066, Ustekinumab; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 12
States / cities: Los Angeles, California • Port Orange, Florida • Arlington Hts, Illinois + 9 more

Conditions: Psoriatic Arthritis
Interventions: Open label H.P. Acthar Gel; Drug
Lead sponsor: Fiechtner, Justus J., M.D., P.C.; Individual
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Lansing, Michigan

Conditions: Atopic Dermatitis, Dermatology, Vitiligo, Alopecia Areata, Hidradenitis Suppurativa, Psoriasis
Interventions: N/A This is an observational study; Other
Lead sponsor: OM1, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Plaque Psoriasis
Interventions: Envudeucitinib, Placebo, Apremilast; Drug
Lead sponsor: Alumis Inc; Industry
Eligibility: 18 Years and older
Enrollment: 862 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 43
States / cities: Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 36 more

Conditions: Chronic Plaque Psoriasis
Interventions: AIN457, Placebo; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 5
States / cities: Santa Monica, California • Louisville, Kentucky • High Point, North Carolina + 2 more

Conditions: Plaque-type Psoriasis
Interventions: secukinumab 150mg, secukinumab 10mg/kg i.v. regimen; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 6
States / cities: Jacksonville, Florida • West Palm Beach, Florida • Boston, Massachusetts + 3 more

Search by objective public record fields.

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

The Effect of Weight Loss on Psoriasis Area Severity Index in Adult Psoriasis Patients

A Study of the Safety and How the Body Affects a Drug (CNTO 1959) in Healthy Volunteers and in Patients With Psoriasis

A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis

A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis

Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis

An Effectiveness and Safety Study of CNTO 1275 in Patients With Active Psoriatic Arthritis

Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast

A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)

Impact of Literacy Level on Patient Education and Health Among People With Arthritis

Study to Evaluate the Pharmacokinetics and the Safety of M518101 in Plaque Psoriasis Patients

Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris

A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

Scalp Psoriasis Treatment With a Fiber Optic Comb

Reduction of Pain Caused by Biologic Drugs in Psoriasis

BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab

Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis

A Prospective, Observational Study of Clinician and Patient-reported Outcomes in Patients With Dermatological Conditions

A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001

Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis

Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis